{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T04:15:51Z","timestamp":1744949751509,"version":"3.40.4"},"reference-count":9,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:p>This Viewpoint discusses how therapy of chronic myeloid leukemia can inform therapy of lung cancer.<\/jats:p>","DOI":"10.1001\/jamaoncol.2024.6727","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T16:01:20Z","timestamp":1740067280000},"page":"369","source":"Crossref","is-referenced-by-count":0,"title":["Can Knowledge From Treating Chronic Myeloid Leukemia Inform Therapy of <i>EGFR<\/i>-Mutant Lung Adenocarcinoma?"],"prefix":"10.1001","volume":"11","author":[{"given":"Robert Peter","family":"Gale","sequence":"first","affiliation":[{"name":"Centre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"7216","key":"cvp240031r1","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma.","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"issue":"7511","key":"cvp240031r2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma.","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"issue":"1","key":"cvp240031r3","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1038\/s41467-024-46284-x","article-title":"Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers.","volume":"15","author":"Iyer","year":"2024","journal-title":"Nat Commun"},{"issue":"7955","key":"cvp240031r4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41586-023-05874-3","article-title":"Lung adenocarcinoma promotion by air pollutants.","volume":"616","author":"Hill","year":"2023","journal-title":"Nature"},{"issue":"2","key":"cvp240031r5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264201","article-title":"Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR.","volume":"17","author":"Williamson","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"cvp240031r6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35565","article-title":"Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia.","volume":"131","author":"Li","year":"2025","journal-title":"Cancer"},{"issue":"7","key":"cvp240031r7","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet Haematol"},{"issue":"18","key":"cvp240031r8","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer.","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"cvp240031r9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.cllc.2022.04.002","article-title":"Clinical utility of liquid biopsy (cell-free DNA) based EGFR mutation detection post treatment initiation as a disease monitoring tool in patients with advanced EGFR-mutant NSCLC.","volume":"23","author":"Behel","year":"2022","journal-title":"Clin Lung Cancer"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2830544\/jamaoncology_gale_2025_vp_240031_1744202980.32529.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T15:01:40Z","timestamp":1744902100000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2830544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.6727","relation":{},"ISSN":["2374-2437"],"issn-type":[{"type":"print","value":"2374-2437"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}